The International Dermatology Outcome Measures (IDEOM) Initiative: A review and update
The International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, industry partners, payers, and regulatory agencies, was established to develop unified and validated patient-centered outcome measures in dermatology in response to increasing demand to quantify effectiveness of treatments and performance outcomes among providers. IDEOM has chosen to start with psoriasis outcome measures, and then apply its methodology to other dermatologic diseases. In this paper, we review the background and progress to date of IDEOM, including an update of IDEOM activities as of our 2016 meeting in Washington DC, USA. Briefly, the progress-to-date of a Delphi process to create outcome measures for psoriasis was reviewed, including preliminary data from the first round of Delphi voting. Updates were also heard from industry partners including the National Psoriasis Foundation (NPF) and the US Food and Drug Administration (FDA). Furthermore, plans to establish outcome measures for hidradenitis suppurative (HS) were discussed.
Elman, S., Merola, J., Armstrong, A., Ruffin, K., Latella, J., Garg, A., & Gottlieb, A. (2017). The International Dermatology Outcome Measures (IDEOM) Initiative: A review and update. Journal of Drugs in Dermatology, 16 (2), 119-124. Retrieved from https://touroscholar.touro.edu/nymc_fac_pubs/413